W. Stöhr

M. Rauh, H. Schneider, J. Dötsch, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Glomerular Dysfunction and Associated Risk Factors over 4–5 Years following Antiretroviral Therapy Initiation in Africa

A. Walker, C. Gilks, D. Gibb, 2011, Antiviral therapy.

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone.

S. McCormack, G. Pantaleo, J. Heeney, 2008, Vaccine.

Prospective evaluation of hepatitis B, C and HIV infections as possible sequelae of antineoplastic treatment in paediatric sarcoma patients: a report from the Late Effects Surveillance System.

S. Bielack, H. Jürgens, T. Klingebiel, 2006, Oncology reports.

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters

H. Rees, P. Kaleebu, G. Ramjee, 2019, AIDS.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Comparison of leptin gene expression in different adipose tissues in children and adults.

T. Horbach, J. Dötsch, W. Rascher, 2004, European journal of endocrinology.

Circulating resistin concentrations in children depend on renal function.

J. Dötsch, W. Rascher, J. Kratzsch, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case–control study

M. Sharland, D. Gibb, D. Dunn, 2010, AIDS.

Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

F. Raffi, D. Carr, G. di Perri, 2022, The Pharmacogenomics Journal.

Prevalence, Incidence and Predictors of Severe Anaemia with Zidovudine-Containing Regimens in African Adults with HIV Infection within the Dart Trial

A. Walker, C. Gilks, J. Darbyshire, 2005, Antiviral therapy.

Exploring people’s resistance to the Active User Paradox including personality traits : an investigation of the relationship between people’s resistance to the Active User Paradox and the role of geekism, need for cognition and computer anxiety

W. Stöhr, 2015 .

Results of the clinical trial

S. Walker, M. Sculpher, D. Dunn, 2016 .

Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication

C. Leen, D. Pillay, A. Winston, 2008, Antiviral therapy.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression

J. Miro, D. Cooper, J. Weber, 2014, AIDS.

Effect of renal failure and dialysis on circulating ghrelin concentration in children.

M. Rauh, J. Dötsch, W. Rascher, 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Hydrochlorothiazide in CLDN16 mutation.

M. Konrad, J. Dötsch, W. Rascher, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Growth impairment after ifosfamide‐induced nephrotoxicity in children

W. Stöhr, T. Langer, J. Beck, 2007, Pediatric blood & cancer.

Ifosfamide‐induced nephrotoxicity in 593 sarcoma patients: A report from the Late Effects Surveillance System

S. Bielack, H. Jürgens, W. Stöhr, 2007, Pediatric blood & cancer.

Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy

C. Leen, A. Winston, C. Orkin, 2013, PloS one.

Cisplatin-Induced Ototoxicity in Osteosarcoma Patients: A Report from the Late Effects Surveillance System

S. Bielack, W. Stöhr, A. Lamprecht-Dinnesen, 2005, Cancer investigation.

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study

S. McCormack, D. Montefiori, N. Frahm, 2016, PloS one.

Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial

A. Winston, M. Johnson, M. Gompels, 2015, The lancet. HIV.

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.

F. Raffi, G. di Perri, L. Vandekerckhove, 2019, The Journal of antimicrobial chemotherapy.

HIV-1 DNA predicts disease progression and post-treatment virological control

M. Carrington, R. Phillips, D. Cooper, 2014, eLife.

Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy

P. Kaleebu, R. Phillips, D. Cooper, 2013, PloS one.

Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection

P. Goulder, W. Stöhr, J. Frater, 2017, AIDS.

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach

A. Winston, M. Johnson, H. Zetterberg, 2021, Journal of virus eradication.

Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

M. Johnson, V. Miller, T. Peto, 2020, The Lancet.

A Randomized Comparison of Antiretroviral Therapy Alone Versus Antiretroviral Therapy with a 'Kick-and-Kill' Approach, on Measures of the HIV Reservoir Amongst Participants with Recent HIV Infection: The RIVER Trial

M. Johnson, M. Wills, A. Clarke, 2019, SSRN Electronic Journal.

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels

J. Miro, D. Cooper, J. Weber, 2015, AIDS.

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy

A. Tostevin, D. Dunn, N. Paton, 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

S. McCormack, G. Pantaleo, J. Heeney, 2008, The Journal of experimental medicine.

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

I. Williams, C. Gilks, D. Gibb, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

ALMOST NORMAL COGNITIVE FUNCTION IN PATIENTS DURING THERAPY FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITHOUT CRANIAL IRRADIATION ACCORDING TO ALL-BFM 95 AND COALL 06-97 PROTOCOLS: Results of an Austrian–German Multicenter Longitudinal Study and Implications for Follow-Up

P. Krappmann, M. Schrappe, W. Stöhr, 2007, Pediatric hematology and oncology.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae

C. Gilks, J. Darbyshire, W. Stöhr, 2008, Antiviral therapy.

Prospective Multicenter Registration of Major Late Sequelae in Sarcoma Patients Using the Late Effects Surveillance System (LESS)

H. Dörr, W. Stöhr, U. Göbel, 2005, Klinische Padiatrie.

Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System.

W. Stöhr, T. Langer, J. Treuner, 2004, Oncology reports.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

S. McCormack, M. Hoelscher, M. Robb, 2018, PloS one.

Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

A. Crook, S. McCormack, Felipe García, 2019, The lancet. HIV.

The evaluation of immune-based approaches to achieve an antiretroviral therapy (ART)-free remission of HIV infection requires demonstration of efficacy through ART interruption placebo-controlled trials

A. Crook, S. McCormack, Felipe García, 2019 .

Glomerular Dysfunction and associated Risk Factors following Initiation of ART in Adults with HIV Infection in Africa: a subanalysis in the DART Trial.

C. Gilks, F. Ssali, W. Stöhr, 2006 .

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

S. McCormack, D. Montefiori, R. Gottardo, 2020, PLoS pathogens.

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997–2003

B. Gazzard, R. Gilson, C. Sabin, 2007, HIV medicine.

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial.

S. Faust, A. Finn, M. Sharland, 2021, JAMA.

Prospective longitudinal evaluation of doxorubicin‐induced cardiomyopathy in sarcoma patients: A report of the late effects surveillance system (LESS)

S. Bielack, H. Jürgens, W. Stöhr, 2006, Pediatric blood & cancer.

Analysis from the NeoOBS Global Neonatal Sepsis Prospective Observational Cohort Study Across 19 Hospitals in 11 Countries; Clinical Presentation, Treatment, Mortality Outcomes and Development of the NeoSEP Sepsis Severity Score

H. Goossens, S. Cousens, M. Sharland, 2021, SSRN Electronic Journal.

Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy

N. Beeching, M. Johnson, K. Sanders, 2016, AIDS.

Genital Secretion HIV RNA Shedding in HIV-Positive Patients on Ritonavir-Boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-Sectional Sub-Study from the PIVOT Trial

N. Beeching, S. Khoo, A. Clarke, 2020, Antiviral therapy.

Evaluation of Cerebrospinal Fluid Virological Escape in Patients on Long-Term Protease Inhibitor Monotherapy

N. Beeching, A. Clarke, I. Williams, 2017, Antiviral therapy.

Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients

S. Walker, M. Sculpher, D. Dunn, 2014, Journal of the International AIDS Society.

Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial

S. Walker, M. Sculpher, D. Dunn, 2016, PharmacoEconomics.

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial

H. Amièva, A. d’Arminio Monforte, A. Winston, 2017, Journal of acquired immune deficiency syndromes.

Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy

H. Amièva, A. Winston, A. Antinori, 2016, HIV medicine.

Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)

H. Goossens, S. Cousens, P. Musoke, 2023, PLoS medicine.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

A. Antinori, F. Raffi, W. Stöhr, 2018, Journal of acquired immune deficiency syndromes.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial

A. Antinori, F. Raffi, W. Stöhr, 2018, Journal of acquired immune deficiency syndromes.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

X. Golay, L. Haddow, A. Winston, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment

A. Winston, J. Ainsworth, J. Day, 2014, PloS one.

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers

S. McCormack, M. Robb, G. Ferrari, 2020, Microorganisms.

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial

B. Moss, S. McCormack, M. Hoelscher, 2015, PloS one.

Tolerability of four‐drug antiretroviral combination therapy in primary HIV‐1 infection

J. Fox, W. Stöhr, M. Nelson, 2021, HIV Medicine.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.

Estimating Glomerular Filtration Rate in HIV-Infected Adults in Africa: Comparison of Cockcroft–Gault and Modification of Diet in Renal Disease Formulae

C. Gilks, J. Darbyshire, W. Stöhr, 2008, Antiviral therapy.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.